1052 related articles for article (PubMed ID: 17112329)
21. Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico.
Briseño GG; Mino-León D
Curr Med Res Opin; 2010 May; 26(5):1075-81. PubMed ID: 20225991
[TBL] [Abstract][Full Text] [Related]
22. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
Miller PS; Smith DG; Jones P
Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635
[TBL] [Abstract][Full Text] [Related]
25. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
[TBL] [Abstract][Full Text] [Related]
26. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Rublee DA; Burke JP
Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
[TBL] [Abstract][Full Text] [Related]
27. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
28. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
McKenney J; Ballantyne CM; Feldman TA; Brady WE; Shah A; Davies MJ; Palmisano J; Mitchel YB
MedGenMed; 2005 Jul; 7(3):3. PubMed ID: 16369229
[TBL] [Abstract][Full Text] [Related]
29. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
Stalenhoef AF; Ballantyne CM; Sarti C; Murin J; Tonstad S; Rose H; Wilpshaar W
Eur Heart J; 2005 Dec; 26(24):2664-72. PubMed ID: 16143705
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice.
Gandhi SK; Järbrink K; Fox KM; Brandrup-Wognsen G
Curr Med Res Opin; 2009 Dec; 25(12):2817-28. PubMed ID: 19916726
[TBL] [Abstract][Full Text] [Related]
31. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Tran YB; Frial T; Miller PS
Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
[TBL] [Abstract][Full Text] [Related]
32. Achieving lipid goals in real life: the Dutch DISCOVERY study.
Bots AF; Kastelein JJ;
Int J Clin Pract; 2005 Dec; 59(12):1387-94. PubMed ID: 16351669
[TBL] [Abstract][Full Text] [Related]
33. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Deedwania PC; Hunninghake DB; Bays HE; Jones PH; Cain VA; Blasetto JW;
Am J Cardiol; 2005 Feb; 95(3):360-6. PubMed ID: 15670545
[TBL] [Abstract][Full Text] [Related]
34. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
Betteridge DJ; Gibson JM
Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
[TBL] [Abstract][Full Text] [Related]
35. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
Betteridge DJ; Gibson JM; Sager PT
Am J Cardiol; 2007 Oct; 100(8):1245-8. PubMed ID: 17920365
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
Brown WV; Bays HE; Hassman DR; McKenney J; Chitra R; Hutchinson H; Miller E;
Am Heart J; 2002 Dec; 144(6):1036-43. PubMed ID: 12486428
[TBL] [Abstract][Full Text] [Related]
37. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Cheung RC; Morrell JM; Kallend D; Watkins C; Schuster H
Int J Cardiol; 2005 Apr; 100(2):309-16. PubMed ID: 15823640
[TBL] [Abstract][Full Text] [Related]
38. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Montouchet C; Ruff L; Balu S
J Med Econ; 2013 Jul; 16(7):907-16. PubMed ID: 23641809
[TBL] [Abstract][Full Text] [Related]
39. Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.
Ohsfeldt RL; Gandhi SK; Fox KM; McKenney JM
Value Health; 2008 Dec; 11(7):1061-9. PubMed ID: 18489494
[TBL] [Abstract][Full Text] [Related]
40. Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting.
Harley CR; Gandhi SK; Anoka N; Bullano MF; McKenney JM
Am J Manag Care; 2007 Dec; 13 Suppl 10():S276-81. PubMed ID: 18095778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
